Biotech Values

[DewDiligence]

PPHM—There is no way of knowing if dual action [MoA] actually occurred in human trials. One way to look at is via adverse event to see if they show up. I haven't seen much indication from adverse events indicating either anti-angiogenic activity or immune response.

Excellent point. To date, the adverse-event profile of Bavituximab is more consistent with its being a placebo than the highly active agent in such disparate diseases as HCV, HIV, and multiple forms of cancer that the company’s management would have investors believe.